Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences' SensiDerm Assays Prioritized by Cosmetics Europe for Further Development


Proteome Sciences said this week that its SensiDerm multiplex protein assays for detection of sensitizers and allergens in cosmetics have been prioritized for further development by Cosmetics Europe, the European trade organization for the cosmetics, toiletry, and perfumery industry.

The assays, which comprise tests for more than 200 patented skin and respiratory markers, emerged from the company's participation in the EU-funded Sens-it-iv project, a research initiative aimed at developing in vitro testing methods that could replace animal testing for cosmetic sensitization studies.

As of March 13, 2013, a ban went into effect in the EU on animal testing of cosmetics ingredients.

Proteome Sciences identified the markers using its mass spec-based proteomic biomarker discovery platform and has developed assays to them using its Tandem Mass Tagging technology combined with selected-reaction monitoring mass spec.

Cosmetics Europe's decision to prioritize the assays means that the company is eligible to receive funding from that organization and the EU for "further development, optimization, and standardization" of the tests, Proteome Sciences said, although it added that details have yet to be agreed upon.

“We look forward to working with Cosmetics Europe to develop our SensiDerm multiplex tests commercially that are rapid, easy to use, and highly sensitive that will provide the means for companies to meet the EU requirement for non-animal testing for sensitizers in their products and in particular dermatological and respiratory allergens," CEO Christopher Pearce said in a statement.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.